About
Meury began his career in public accounting at Reznick, Fedder & Silverman and in financial reporting at MCI Communications, then joined Forest Laboratories in 1993, where he became Executive Vice President, Sales and Marketing. He held Allergan roles from 2014 to 2016 and was its Chief Commercial Officer from 2016 to 2020. He then worked as a partner at Hildred Capital Management. At Incyte he followed Hervé Hoppenot, who retired as CEO in June 2025. Other biotech chief executives with pages on Whoo include Kyle Gano of Neurocrine Biosciences and Michael Morrissey of Exelixis.
He was CEO of Karuna Therapeutics from January 2023 to March 2024, when Bristol-Myers Squibb acquired it, and of Anthos Therapeutics from April 2024 to April 2025, when Novartis acquired it.
Whoo compiled this page from public sources: Incyte 2026 proxy statement (SEC), Incyte Form 10-Q, September 2026 (SEC), Wikipedia: Incyte. It is not affiliated with or endorsed by Bill Meury. Are you Bill Meury? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
Chief Executive Officer — Incyte
2025 – Present | Wilmington, Delaware
- Joined Incyte in June 2025 and serves as CEO and director
- Led the private company until Novartis acquired it
- Led the public company until Bristol-Myers Squibb acquired it
- Held earlier Allergan roles from 2014 to 2016
- Joined Forest in 1993; Actavis acquired the company in July 2014
President and CEO — Anthos Therapeutics
April 2024 – April 2025
President and CEO — Karuna Therapeutics
January 2023 – March 2024
Partner — Hildred Capital Management
May 2020 – December 2022
Chief Commercial Officer — Allergan
May 2016 – May 2020
Executive Vice President, Sales and Marketing — Forest Laboratories
1993 – 2014
Education
Education
Not published in sources